A Phase 1 interventional study of cytisine and placebo in Smoking Cessation, sponsored by Achieve Life Sciences. Completed at 1 site in Portugal. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-17.
Sponsored by Achieve Life Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing cytisine in Smoking Cessation — 3 open to participants now, 5 under way, 1 of them phase 3. cytisine · Smoking Cessation.
Among the 22 studies testing cytisine in Smoking Cessation, this one is the 13th largest by enrollment, is one of 2 that started in 2019, is one of 6 in phase 1, and was the 8th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →3 of the 22 studies testing cytisine in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States
Ages 18–65
Centre for Addiction and Mental Health
Ages 18+
Maimónides Biomedical Research Institute of Córdoba
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 7 · Phase 4 3
First in 2016; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is below the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 202 across the 22 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
Achieve Life Sciences is the lead sponsor of 31 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 8 (67%) have results posted.
10 studies in Smoking Cessation by Achieve Life Sciences: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 10 studies in Smoking Cessation by Achieve Life Sciences, this one is the 5th largest by enrollment, is the only one that started in 2019, is one of 5 in phase 1, and was the 5th registered.
Achieve Life Sciences’s Smoking Cessation studies by the year they started, since 2017.
1 of the studies testing cytisine in Smoking Cessation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06617312University of California, Los AngelesExamining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing cytisine in Smoking Cessation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Achieve Life Sciences’s 10 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of this study are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet ALL of the following criteria to be eligible for inclusion into the study:
Exclusion Criteria:
Subjects meeting ANY of the following exclusion criteria will NOT be eligible for inclusion into the study at screening.
Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.
Subjects meeting ANY of the following exclusion criteria will NOT be eligible for inclusion into the study at admission to each cohort.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: cytisine
Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: placebo
Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: cytisine
Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: placebo
Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: cytisine
Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: placebo
Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: cytisine
Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: placebo
Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: cytisine
Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: placebo
Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: cytisine
Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: placebo
Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: cytisine
Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: placebo
Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: cytisine
Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: placebo
Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: cytisine
Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
Drug: placebo
cytisine film-coated oral tablet
Also known as: Tabex, cytisinicline
matching placebo oral tablet
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Study Discontinuation
An adverse event (AE) is defined as any untoward medical occurrence that does not necessarily have to have a causal relationship with the treatment. A serious AE is any untoward medical occurrence or effect, that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; or is an important medical event which requires medical intervention to prevent one of the above. Treatment emergent events are those that occurred after the first dose of study drug.
Time frame: From first dose of study drug through Day 6
Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)
Time frame: Day 1: Pre-dose (within 30 minutes prior to dosing), 15, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours (+/-2 minutes) post-dose
Pharmacokinetics: Time to Occurrence of Cmax (Tmax)
Time frame: Day 1: Pre-dose (within 30 minutes prior to dosing), 15, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours (+/-2 minutes) post-dose
Participants were enrolled in a single center in Portugal.
| Milestone | Placebo | Cytisine 6 mg | Cytisine 9 mg | Cytisine 12 mg | Cytisine 15 mg | Cytisine 18 mg | Cytisine 21 mg | Cytisine 24 mg | Cytisine 27 mg | Cytisine 30 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 18 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Completed | 18 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) is defined as any untoward medical occurrence that does not necessarily have to have a causal relationship with the treatment. A serious AE is any untoward medical occurrence or effect, that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; or is an important medical event which requires medical intervention to prevent one of the above. Treatment emergent events are those that occurred after the first dose of study drug.
| participants | Placebo | Cytisine 6 mg | Cytisine 9 mg | Cytisine 12 mg | Cytisine 15 mg | Cytisine 18 mg | Cytisine 21 mg | Cytisine 24 mg | Cytisine 27 mg | Cytisine 30 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | 5 | 2 | 1 | 4 | 3 | 2 | 1 | 2 | 2 | 4 |
| Serious TEAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TEAE Leading to Study Discontinuation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ng/mL | Cytisine 6 mg | Cytisine 9 mg | Cytisine 12 mg | Cytisine 15 mg | Cytisine 18 mg | Cytisine 21 mg | Cytisine 24 mg | Cytisine 27 mg | Cytisine 30 mg |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) | 71.05 (56.07 to 86.03) | 93.62 (79.44 to 107.79) | 94.27 (74.87 to 113.66) | 126.45 (100.82 to 152.07) | 134.94 (107.00 to 162.88) | 150.08 (114.12 to 186.04) | 171.44 (149.31 to 193.57) | 151.05 (122.01 to 180.08) | 166.65 (120.95 to 212.34) |
| hours | Cytisine 6 mg | Cytisine 9 mg | Cytisine 12 mg | Cytisine 15 mg | Cytisine 18 mg | Cytisine 21 mg | Cytisine 24 mg | Cytisine 27 mg | Cytisine 30 mg |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics: Time to Occurrence of Cmax (Tmax) | 0.83 (0.50 to 2.00) | 1.38 (0.83 to 2.50) | 1.88 (1.25 to 2.50) | 1.88 (0.50 to 2.50) | 2.00 (1.50 to 3.00) | 1.89 (1.25 to 3.00) | 2.50 (0.83 to 3.00) | 2.75 (1.75 to 3.00) | 2.50 (1.00 to 3.00) |
Collected over From first dose of study drug through Day 6. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/18 (0%) | 0/18 (0%) | 5/18 (27.8%) |
| Cytisine 6 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Cytisine 9 mg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Cytisine 12 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Cytisine 15 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Cytisine 18 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Cytisine 21 mg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Cytisine 24 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Cytisine 27 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Cytisine 30 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Event | Placebo | Cytisine 6 mg | Cytisine 9 mg | Cytisine 12 mg | Cytisine 15 mg | Cytisine 18 mg | Cytisine 21 mg | Cytisine 24 mg | Cytisine 27 mg | Cytisine 30 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/18 | 1/6 | 1/6 | 2/6 | 1/6 | 2/6 | 0/6 | 2/6 | 0/6 | 1/6 |
| VomitingGastrointestinal disorders | 0/18 | 1/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/6 | 0/6 | 2/6 |
| PresyncopeNervous system disorders | 0/18 | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/18 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/18 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| DyspepsiaGastrointestinal disorders | 0/18 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| FlatulenceGastrointestinal disorders | 0/18 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| Vessel puncture site haemorrhageGeneral disorders | 0/18 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Oral herpesInfections and infestations | 0/18 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Back painMusculoskeletal and connective tissue disorders | 2/18 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 |
| Age, Continuous(years) | Placebo | Cytisine 6 mg | Cytisine 9 mg | Cytisine 12 mg | Cytisine 15 mg | Cytisine 18 mg | Cytisine 21 mg | Cytisine 24 mg | Cytisine 27 mg | Cytisine 30 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 31.3 ± 7.5 | 44.5 ± 12.1 | 35.7 ± 8.2 | 35.3 ± 11.1 | 34.7 ± 7.5 | 37.8 ± 12.9 | 30.3 ± 8.1 | 30.0 ± 5.5 | 30.3 ± 4.6 | 29.7 ± 8.9 | 33.5 ± 9.2 |
| Sex: Female, Male(Participants) | Placebo | Cytisine 6 mg | Cytisine 9 mg | Cytisine 12 mg | Cytisine 15 mg | Cytisine 18 mg | Cytisine 21 mg | Cytisine 24 mg | Cytisine 27 mg | Cytisine 30 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 10 | 4 | 2 | 2 | 3 | 2 | 2 | 2 | 1 | 0 | 28 |
| Male | 8 | 2 | 4 | 4 | 3 | 4 | 4 | 4 | 5 | 6 | 44 |
| Race/Ethnicity, Customized(Participants) | Placebo | Cytisine 6 mg | Cytisine 9 mg | Cytisine 12 mg | Cytisine 15 mg | Cytisine 18 mg | Cytisine 21 mg | Cytisine 24 mg | Cytisine 27 mg | Cytisine 30 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 18 | 6 | 6 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 71 |
| Multiple Races | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2019 to primary completion in Sep 2019, 6 months.
Results were first posted in Sep 2020, 1 year after primary completion.
Of 34 phase 1 interventional studies under Smoking Cessation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 34. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cytisine